Connect with us

News

Canntab to Launch in Australia and Participate in Australia’s Largest Cannabis Research Study

TORONTO, Oct. 26, 2020 /CNW/ – Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the “Company” or “Canntab“), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce the impending launch of its suite of hard pill cannabinoid formulations in Australia with its partner CANN Global Ltd. (ASX: CGB) (“CANN […]

The post Canntab to Launch in Australia and Participate in Australia’s Largest Cannabis Research Study appeared first on CannabisFN.

Republished by Plato

Published

on

TORONTOOct. 26, 2020 /CNW/ – Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the “Company” or “Canntab“), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce the impending launch of its suite of hard pill cannabinoid formulations in Australia with its partner CANN Global Ltd. (ASX: CGB) (“CANN Global”)

CANN Global through its management partnership with Medcan Australia Pty Ltd (“Medcan Australia”),  received an import permit and have placed an initial order for Canntab’s products. Canntab will immediately apply for an export permit with Health Canada, which will allow it to fulfill this purchase order. The Company intends to ship its suite of Patented and Patent Pending products, including THC, CBD and THC/CBD combination hard pill formulations to CANN Global before the end of 2020. Once the products are shipped to CANN Global in Australia, the products will be distributed throughout Australia to  medical distributors, including Doctors, Pharmacies, and Hospitals.

Applied Cannabis Research Observational Study

Applied Cannabis Research (“ACR”), a leading Australian contract research organization focused exclusively on medical cannabis treatments, has launched Australia’s largest observational study ever undertaken for medical cannabis. Canntab, through the products it supplies to CANN Global Ltd., which is a direct participant in the study, will be participating in this clinical collaboration with major Australian clinics and hospitals to complete the Cannabinoid Medicine Observational Study (“CMOS”) that will collect data from 20,000 patients nationwide over 5 years. CMOS aims to assess the safety and efficacy of medicinal cannabis products for a range of refractory conditions including fibromyalgia, chronic pain syndromes, PTSD, epilepsy and other mental health and neurological conditions using cannabis, including Canntab’s Hard Pill Cannabinoid Formulations. ACR will lead the study in conjunction with Australia’s medical community and key industry partners such as Althea Group Holdings , Cronos Australia , Cymra Life Sciences , Medcan Australia and Cann Global.

“This deal is two years in the making and represents important milestones for our company,” explains Larry Latowsky, Chief Executive Officer of Canntab. Mr. Latowsky continues, “it is the first of what will be many international alliances and agreements to export our patented products for distribution through our partners’ networks, and it is the first observational clinical study that we are confident will support our vision of our product as unique, effective and the preferred cannabinoid delivery system for many medical symptoms and conditions.”

Sholom Feldman, CANN Global’s Managing Director says: “We are very excited to progress the launch of Canntab’s innovative cannabis-based tablets in Australia which we expect will be very sought-after by Doctors who are looking to prescribe pharmaceutical grade medicinal Cannabis products to their patients. It is our understanding from discussions with medical professionals that it is easier for them to prescribe a uniform dosage tablet produced to pharmaceutical grade standards compared to unreliability of delivery methods used by other products already on the market, giving our product a solid competitive advantage.”

The legal cannabis market is expected to be worth US$1.55 billion by 2024 in AustraliaNew Zealand and the surrounding islands, with medicinal cannabis accounting for approximately 40% of the market1.

Australia is expected to account for 79% of the region’s overall market by 2024, due to a comparably larger population and higher household disposable income than New Zealand and the islands across the region.

About Canntab Therapeutics

Canntab Therapeutics is a Canadian biopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations.  Canntab’s proprietary hard pill cannabinoid formulations provide doctors, patients and consumers with medical grade solutions which incorporate all the features one would expect from any prescription or over the counter medication sold in Canadian pharmacies. These will include the following formulations: once a day and extended release, both providing an accurate dose and improved shelf stability.

Canntab holds a Cannabis Standard Processing & Sales for Medical Purposes Licence, a Cannabis Research Licence, and an Industrial Hemp Licence from Health Canada.

Canntab trades on the Canadian Securities Exchange under the symbol PILL, on the OTCQB under the symbol CTABF, and on the Frankfurt Stock Exchange under the symbol TBF1.

Cautionary Statements

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain information in this press release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or negatives of these terms and similar expressions. Forward- looking statements are based on certain assumptions, including the approval by Health Canada of the Company’s application for an export licence, the delivery to CANN Global of the Company’s products prior to the end of 2020, and the planned distribution of the Company’s products by Medan Australia , and general business, economic, competitive, political and social uncertainties will not prevent the Company from conducting its business. While Canntab considers these assumptions to be reasonable, based on information currently available, they are inherently subject to significant business, economic and competitive uncertainties and contingencies and they may prove to be incorrect. Readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements also necessarily involve known and unknown risks, including without limitation, risks associated with Health Canada not approving the Company’s application for an export licence, delays in fulfilling CANN Global’s purchase order, general economic conditions, adverse industry events, marketing costs, loss of markets, future legislative and regulatory developments, the inability to access sufficient capital on favourable terms, the medical and recreational cannabis industry in Australia in general, income tax and regulatory matters, the ability of Canntab to execute its business strategies, competition, crop failure, currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ from those anticipated. Forward-looking statements are not guarantees of future performance. Except as required by law, Canntab disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, events or otherwise. Forward- looking statements contained in this news release are expressly qualified by this cautionary statement.

SOURCE Canntab Therapeutics Limited

For further information: Canntab Therapeutics Limited, Larry Latowsky, Chief Executive Officer, +1 833-301-3812, [email protected]

Related Links

https://canntab.ca/

Source: https://www.cannabisfn.com/canntab-to-launch-in-australia-and-participate-in-australias-largest-cannabis-research-study/

News

California: 27% of menopausal women use Cannabis to Manage Menopause Symptoms

  Every year, more than 2 million women reach menopause, while 27 million go through the throes of menopause. Defined as the…

The post California: 27% of menopausal women use Cannabis to Manage Menopause Symptoms first appeared on CBD.CI CBD Living.

Republished by Plato

Published

on

Every year, more than 2 million women reach menopause, while 27 million go through the throes of menopause. Defined as the end of a woman’s menstrual cycle, menopausal women experience a natural decline in reproductive function with common symptoms such as hot flashes, night sweats, and mood disorders. Cannabis appears to be a natural solution available to relieve these symptoms.

How cannabis affects menopause 

Researchers associated with the San Francisco VA Medical Center interviewed 232 women (average age 56) living in Northern California and participated in the Midlife Veterans Health Survey, focusing on their management of menopause. This study is available by clicking here.

More than half of them reported embarrassing symptoms such as hot flashes and night sweats (54%), insomnia (27%), and genitourinary symptoms (69%).

  • Approximately 27% of those sampled reported using or currently using cannabis to manage their symptoms.
  • Another 10% of participants expressed interest in trying cannabis to manage menopausal symptoms in the future. More surprisingly, the survey found that women were more likely to use cannabis than traditional menopause therapy such as hormone treatment:
  • Only 19% reported using a more traditional type of menopausal symptom management such as hormone therapy.

Results that prove the place of cannabis in natural alternatives 

These results suggest that using cannabis to manage menopausal symptoms may be relatively common,” said Carolyn Gibson, lead author of the study.

However, we don’t know whether cannabis use is safe or effective for the management of menopausal symptoms or whether women discuss these decisions with their health care providers – particularly in IL, where cannabis is considered an illegal substance under federal guidelines”.

Cannabis use was most often reported by women with hot flashes and night sweats, who represented more than half of those surveyed. About one-quarter of women reported insomnia, while 69% had frequent genitourinary symptoms.

Given the relatively high rate of cannabis use among women in this cohort, scientists and others would be well advised to further explore its safety, efficacy, and prevalence in postmenopausal women.

The researchers agreed with this sentiment, concluding that, while promising, the results of the small sample size required further investigation.

California: 27% of menopausal women use Cannabis to Manage Menopause Symptoms
Article Name
California: 27% of menopausal women use Cannabis to Manage Menopause Symptoms
Description
Defined as the end of a woman’s menstrual cycle, menopausal women experience common symptoms such as hot flashes, night sweats, and mood disorders. Cannabis appears to be a natural solution available to relieve these symptoms.
Publisher Name
Publisher Logo

What’s your reaction?

Source: https://www.cbd.ci/health/california-27-of-menopausal-women-use-cannabis-to-manage-menopause-symptoms/

Continue Reading

News

Zoro celebrates three years of continuous growth

Avatar

Published

on

Zoro celebrates three years of continuous growth

Zoro, UK supplier of fasteners, tools, and equipment to businesses within the engineering sector, is celebrating its third year of continuous growth with a team twice the size and an increased product range to that it started with.

Since 2017, Zoro has gone from strength to strength, with plans to increase staff by another quarter within the next year. The number of products Zoro has sold has also doubled to 300,000 items of PPE, tools, fasteners and equipment, including big name brands. Since January 2020 alone, the company has launched over 97,000 new products.

Zoro UK is daughter company to Fortune 500 company Grainger Global, which was founded in 1927, and has more than 3.2 million businesses and institutions that purchase maintenance, repair and operations (MRO) products. Zoro supplies PPE and equipment to more than 126,000 companies in the engineering, automotive, aerospace, rail, marine and construction markets across the UK.

Chris Matenaers, marketing director at Zoro UK, said: “With around 19% of the UK’s workforce employed in the engineering sector, it is essential that companies have a reliable source of quality equipment, tools and, most importantly, PPE.”

Throughout 2020, despite being a challenging year for many businesses, the Zoro Category Management Team have been able to increase the number of suppliers by ten percent to overcome supply chain issues.

Matenaers believes one of the key reasons for strong and steady growth, apart from competitive pricing and a strong product range, is the flexible trade accounts.

“With office-based teams currently working from home, our multi-user accounts allow for easy collaboration for teams to order the supplies they need. We understand how important next-day delivery and reliable customer service is and we are striving to keep up with demand.”

Zoro’s Business Accounts offers multi-user access, a feature developed for home working. All purchases made by users on the business account will contribute towards the company’s tiered pricing discounts scheme. Other features also include order subscription, introduced to reduce admin, easy-share quotations and multi-user accounts with capped spending.

https://www.zoro.co.uk

Tags

Share This Article

Subscribe to our FREE Newsletter

Related Articles

Most recent Articles

Source: https://www.aero-mag.com/zoro-celebrates-three-years-of-continuous-growth/

Continue Reading

News

Will Donald Trump gratify cannabis prisoners before leaving the White House?

  On Wednesday, some celebrities, republican leaders, and civil rights activists delivered a letter to President Trump appealing for pardons or reparations…

The post Will Donald Trump gratify cannabis prisoners before leaving the White House? first appeared on CBD.CI CBD Living.

Republished by Plato

Published

on

On Wednesday, some celebrities, republican leaders, and civil rights activists delivered a letter to President Trump appealing for pardons or reparations of federal marijuana prisoners for nonviolent cannabis-related crimes.

The letter states that the signatories “firmly believe that justice requires the exercise of executive clemency in these cases. “It is accompanied by a specific list of 24 people who are currently behind bars for cannabis-related offenses, many of whom are serving life sentences.

Weldon Angelos, who was himself sentenced to a mandatory minimum sentence for cannabis before a court reduced his sentence and released him, had already submitted a draft of the letter to the White House in March.

You have expressed support for the right of states to enforce their cannabis laws, especially for medical purposes,” wrote the signatories, including former NBA star Kevin Garnett. “And while there are several proposals before Congress to finally end the ban on cannabis, they tend to lack any real relief for those serving time for selling cannabis.

Given the timidity of this bill, the impasse in Congress, and the imperative of freedom, clemency is the right tool to resolve this problem,” he said. You and you alone have the power to call for the great hypocrisy of previous administrations. While cannabis has become a thriving legal market and has enriched many, your predecessors ignored those serving long federal sentences for doing the same thing.

Among the more than 50 signatories to the news, the letter is Alice Johnson, who appeared at the Republican National Convention and whose story was featured in pro-Trump ads after her drug sentence was overturned by the president.

Legislators from the Republican states of Kansas, Maine, and Missouri also signed, as did actor Danny Trejo, New Haven, Missouri Police Chief Danny Trejo, and former New Mexico Governor and presidential candidate Gary Johnson. They were joined by representatives of associations such as #cut50, Marijuana Policy Project, and Law Enforcement Action Partnership.

To date, during his administration, Trump has granted 27 pardons and 11 commutations. The signatories of this letter expect to see an increase in inclemency from the Executive Board in the coming weeks, as is the case in the last weeks of a presidency.

It is ridiculous that we currently have a billionaire in the cannabis industry, but let’s keep some people in jail for doing the same thing. This is just another example of a useless and destructive criminal justice system,” he said in a press release. I am confident that President Trump will strongly consider correcting some of the most egregious sentences we have brought to his attention.

He is the first president in modern history to commute several sentences during his first years in office,” he said. Traditionally, pardons and commutations take place at the end of a presidency, so this model reassures us that we will get justice for some of them.

No one knows, of course, how Trump will react to the demand for a series of cannabis-specific clemency measures.

Will Donald Trump gratify cannabis prisoners before leaving the White House?
Article Name
Will Donald Trump gratify cannabis prisoners before leaving the White House?
Description
On Wednesday, some celebrities, republican leaders, and civil rights activists delivered a letter to President Trump appealing for pardons or reparations of federal marijuana prisoners for nonviolent cannabis-related crimes.
Publisher Name
Publisher Logo

What’s your reaction?

Source: https://www.cbd.ci/news/will-donald-trump-gratify-cannabis-prisoners-before-leaving-the-white-house/

Continue Reading
CBD2 days ago

CBD News: CBD court ruling brings additional support in Germany for access

Heartland4 days ago

Lebanon Legalized Medical Cannabis, 1st in Arab World

Heartland4 days ago

Lebanon Legalized Medical Cannabis, 1st in Arab World

Heartland4 days ago

Lebanon Legalized Medical Cannabis, 1st in Arab World

Heartland5 days ago

Mounce: Hemp in Mexico and Texas: Pot Luck?

CBD1 day ago

GreenheartCBD Founder Paul Walsh named to the All-Ireland Business All Star List

Metal3 days ago

RINL subsidiary BSLC seeks to make dolomite supplies to other steel mills

Heartland4 days ago

CBD4 days ago

What Is CBD: The Complete Beginner’s Guide

Heartland5 days ago

Heartland5 days ago

Material3 days ago

Gamma radiation modified the optical, electrical, and antibacterial characterization of CuONPs doped in Polyethylene Oxide/Polyvinyl Alcohol

Heartland3 days ago

REVIEW: High Five Duo

Material3 days ago

Fabrication and characterization of nanostructured zinc oxide on printed microcontact electrode for piezoelectric applications

Heartland5 days ago

Material5 days ago

Structural analysis and magnetic characterization of ternary alloys (Co–Fe–Ni) synthesized by mechanical alloying

Manufacturing4 days ago

Building Fundamentals of Manufacturing

Heartland5 days ago

CBD for IBS? M/28/NY

Heartland5 days ago

Material5 days ago

PtOx-TiO2 anatase nanomaterials for photocatalytic reformation of methanol to hydrogen: effect of TiO2 morphology

Heartland4 days ago

CBD Full Spectrum Distillate

Uncategorized3 days ago

Did Joe Biden and Kamala Harris Just Pull A Fast One On The Cannabis Industry?

Heartland5 days ago

Material5 days ago

Synthesis and photocatalytic investigation of ZnFe2O4 in the degradation of organic dyes under visible light

Heartland5 days ago

This is what 58 looks like: Mother-of-four says daily bathing rituals, CBD cream and menopause …

Heartland5 days ago

Less Indiana hemp went to pot in 2020

Heartland5 days ago

I’m sure this has been asked before but I can’t seem to find a consensus. What is the best brand/product to take for strictly sleep. Are there any specific sleeping blends out there?

Heartland5 days ago

Heartland4 days ago

Heartland4 days ago

Trending

A Cloud Nine Capital Entity Copyright © 2020 – All Rights Reserved Proudly Made in America